Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study

Manfredi Rizzo, Manisha Chandalia, Angelo M. Patti, Vittoria Di Bartolo, Ali A. Rizvi, Giuseppe Montalto, Nicola Abate

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Background: Liraglutide, a long-acting glucagon-like peptide-1 (GLP-1) analog, has several non- glycemic properties, but its effect on carotid intima-media thickness (IMT), a recognized marker of subclinical atherosclerosis, is still unknown.Methods: A prospective study of 8 months duration in 64 patients with type-2 diabetes and no prior history of coronary artery disease evaluated whether adding liraglutide to metformin affects carotid IMT, measured by color doppler ultrasound.Results: After 8 months, fasting glucose decreased by 2.1 mmol/l and HbA1c by 1.9% (p < 0.01 for all). Liraglutide reduced total-cholesterol and triglycerides by 10%, and LDL-cholesterol by 19%, whereas HDL-cholesterol increased by 18% (p < 0.01 for all lipid changes). Carotid IMT decreased from 1.19 ± 0.47 to 0.94 ± 0.21 mm (p < 0.01). Yet, changes in carotid IMT did not correlate with changes in any other variable studied.Conclusions: Liraglutide decreases carotid IMT after 8 months treatment independently of its effect on plasma glucose and lipids concentrations.Trial registration: ClinicalTrials.gov: NCT01715428.

Original languageEnglish (US)
Article number49
JournalCardiovascular Diabetology
Volume13
Issue number1
DOIs
StatePublished - Feb 22 2014

Fingerprint

Carotid Intima-Media Thickness
Type 2 Diabetes Mellitus
Prospective Studies
Lipids
Glucose
Doppler Ultrasonography
Glucagon-Like Peptide 1
Metformin
LDL Cholesterol
HDL Cholesterol
Coronary Artery Disease
Fasting
Atherosclerosis
Triglycerides
Color
Cholesterol
Liraglutide

Keywords

  • Cardiovascular risk
  • Carotid intima-media thickness
  • Liraglutide
  • Type2 diabetes

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes : 8-month prospective pilot study. / Rizzo, Manfredi; Chandalia, Manisha; Patti, Angelo M.; Di Bartolo, Vittoria; Rizvi, Ali A.; Montalto, Giuseppe; Abate, Nicola.

In: Cardiovascular Diabetology, Vol. 13, No. 1, 49, 22.02.2014.

Research output: Contribution to journalArticle

Rizzo, Manfredi ; Chandalia, Manisha ; Patti, Angelo M. ; Di Bartolo, Vittoria ; Rizvi, Ali A. ; Montalto, Giuseppe ; Abate, Nicola. / Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes : 8-month prospective pilot study. In: Cardiovascular Diabetology. 2014 ; Vol. 13, No. 1.
@article{5736fb75b2d543bcb39111bfce194f19,
title = "Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study",
abstract = "Background: Liraglutide, a long-acting glucagon-like peptide-1 (GLP-1) analog, has several non- glycemic properties, but its effect on carotid intima-media thickness (IMT), a recognized marker of subclinical atherosclerosis, is still unknown.Methods: A prospective study of 8 months duration in 64 patients with type-2 diabetes and no prior history of coronary artery disease evaluated whether adding liraglutide to metformin affects carotid IMT, measured by color doppler ultrasound.Results: After 8 months, fasting glucose decreased by 2.1 mmol/l and HbA1c by 1.9{\%} (p < 0.01 for all). Liraglutide reduced total-cholesterol and triglycerides by 10{\%}, and LDL-cholesterol by 19{\%}, whereas HDL-cholesterol increased by 18{\%} (p < 0.01 for all lipid changes). Carotid IMT decreased from 1.19 ± 0.47 to 0.94 ± 0.21 mm (p < 0.01). Yet, changes in carotid IMT did not correlate with changes in any other variable studied.Conclusions: Liraglutide decreases carotid IMT after 8 months treatment independently of its effect on plasma glucose and lipids concentrations.Trial registration: ClinicalTrials.gov: NCT01715428.",
keywords = "Cardiovascular risk, Carotid intima-media thickness, Liraglutide, Type2 diabetes",
author = "Manfredi Rizzo and Manisha Chandalia and Patti, {Angelo M.} and {Di Bartolo}, Vittoria and Rizvi, {Ali A.} and Giuseppe Montalto and Nicola Abate",
year = "2014",
month = "2",
day = "22",
doi = "10.1186/1475-2840-13-49",
language = "English (US)",
volume = "13",
journal = "Cardiovascular Diabetology",
issn = "1475-2840",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes

T2 - 8-month prospective pilot study

AU - Rizzo, Manfredi

AU - Chandalia, Manisha

AU - Patti, Angelo M.

AU - Di Bartolo, Vittoria

AU - Rizvi, Ali A.

AU - Montalto, Giuseppe

AU - Abate, Nicola

PY - 2014/2/22

Y1 - 2014/2/22

N2 - Background: Liraglutide, a long-acting glucagon-like peptide-1 (GLP-1) analog, has several non- glycemic properties, but its effect on carotid intima-media thickness (IMT), a recognized marker of subclinical atherosclerosis, is still unknown.Methods: A prospective study of 8 months duration in 64 patients with type-2 diabetes and no prior history of coronary artery disease evaluated whether adding liraglutide to metformin affects carotid IMT, measured by color doppler ultrasound.Results: After 8 months, fasting glucose decreased by 2.1 mmol/l and HbA1c by 1.9% (p < 0.01 for all). Liraglutide reduced total-cholesterol and triglycerides by 10%, and LDL-cholesterol by 19%, whereas HDL-cholesterol increased by 18% (p < 0.01 for all lipid changes). Carotid IMT decreased from 1.19 ± 0.47 to 0.94 ± 0.21 mm (p < 0.01). Yet, changes in carotid IMT did not correlate with changes in any other variable studied.Conclusions: Liraglutide decreases carotid IMT after 8 months treatment independently of its effect on plasma glucose and lipids concentrations.Trial registration: ClinicalTrials.gov: NCT01715428.

AB - Background: Liraglutide, a long-acting glucagon-like peptide-1 (GLP-1) analog, has several non- glycemic properties, but its effect on carotid intima-media thickness (IMT), a recognized marker of subclinical atherosclerosis, is still unknown.Methods: A prospective study of 8 months duration in 64 patients with type-2 diabetes and no prior history of coronary artery disease evaluated whether adding liraglutide to metformin affects carotid IMT, measured by color doppler ultrasound.Results: After 8 months, fasting glucose decreased by 2.1 mmol/l and HbA1c by 1.9% (p < 0.01 for all). Liraglutide reduced total-cholesterol and triglycerides by 10%, and LDL-cholesterol by 19%, whereas HDL-cholesterol increased by 18% (p < 0.01 for all lipid changes). Carotid IMT decreased from 1.19 ± 0.47 to 0.94 ± 0.21 mm (p < 0.01). Yet, changes in carotid IMT did not correlate with changes in any other variable studied.Conclusions: Liraglutide decreases carotid IMT after 8 months treatment independently of its effect on plasma glucose and lipids concentrations.Trial registration: ClinicalTrials.gov: NCT01715428.

KW - Cardiovascular risk

KW - Carotid intima-media thickness

KW - Liraglutide

KW - Type2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=84895762544&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895762544&partnerID=8YFLogxK

U2 - 10.1186/1475-2840-13-49

DO - 10.1186/1475-2840-13-49

M3 - Article

C2 - 24559258

AN - SCOPUS:84895762544

VL - 13

JO - Cardiovascular Diabetology

JF - Cardiovascular Diabetology

SN - 1475-2840

IS - 1

M1 - 49

ER -